A leukemia therapy that Novartis (NVS) bought from the University of Pennsylvania has freed nine out of 12 patients of the blood cancer. The treatment works by taking the sufferers' immune cells, reprogramming them to target leukemia cells, and then re-injecting them into the patients. Novartis will call the treatment CTL019.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Nasdaq.com (Fri, 9:00AM)
at Zacks.com (Feb 24, 2015)
at Investor's Business Daily (Feb 23, 2015)
at Benzinga.com (Feb 23, 2015)
at Investor's Business Daily (Jan 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs